Treatment with HMG-CoA reductase inhibitors, commonly known as statins, is beneficial for people at high risk of a cardiovascular event. However, guidelines recommend against routine statin treatment for those with a lower risk. They also recommend waiting until after 45 years of age to assess cardiovascular risk in healthy individuals. Aboriginal and Torres Strait islander people should be assessed from age 35 years. These recommendations are based on current evidence of who is more likely to benefit from statin treatment.
greater rates of physical inactivity, obesity and diabetes all threaten this trend. 1 The absolute risk of developing cardiovascular disease is predictable using risk calculation tools. 2 Statins are known to reduce this risk in people with existing ischaemic cardiovascular disease, or those at high risk of developing it − defined as more than 15% risk of an event in five years. However it is less clear whether people with a lower cardiovascular risk, benefit from statins.
Statin use
The number of patients diagnosed with high cholesterol has doubled between 2004 and 2009. 3 The focus on single risk factors like cholesterol translates to 27% of adult general practice patients being managed for cholesterol 4 − three-quarters of them are treated with statins.
Patients and health providers alike tend to focus on cholesterol, perhaps because it is an easy target to test and treat. A possible consequence of this is that statins are the most prescribed of all drugs both in quantity and cost on the Pharmaceutical Benefits Scheme (PBS). There are three individual statins in the top 10 of all prescribed drugs -atorvastatin, simvastatin and rosuvastatin. 5 Suggestions have been made about both under-and over-prescribing of statins in Australia. Women are far more likely to be treated with statins relative to their risk for cardiovascular disease than men, with the exception of men in the highest socioeconomic group. Rural people are less likely to be treated with a statin. 6 
Cardiovascular risk
The term cardiovascular risk refers to the risk of ischaemic disease defined as acute coronary events, angina, stroke, transient This is sometimes confused with familial hypercholesterolaemia (LDL >4.9 mmol/L usually with tendon xanthoma) which affects 1 in 500 (0.2%) people. 9 This is a high risk condition and results in coronary heart disease or stroke at a young age (under 60 years).
Risk calculation
Calculating absolute risk using Framingham data adapted for Australia is well validated, based on multiple factors including cholesterol levels, but is underused. 2 is no evidence of benefit from statin therapy on all-cause mortality. 13 This suggests that caution should be used when recommending statins for primary prevention of cardiovascular disease in those at low risk (that is with a risk of cardiovascular disease less than 2% in one year) because of limited benefit and a potential for harm (Table 2) . 15, 16 In those with moderate to severe chronic kidney disease, statin treatment reduces cardiovascular events but not overall mortality. 17 However, statin treatment of those with less severe chronic kidney disease appears to reduce cardiovascular events and overall mortality. 18
PBS listing
The PBS general statement for using lipid-lowering drugs defines patients at risk who would be expected to benefit from statin therapy. The wording is intended to mirror the absolute cardiovascular disease risk calculation, but is an imperfect match.
Conclusion
It is likely that we are over-prescribing statins to low-risk 
Top 10 drugs
These tables show the top 10 subsidised drugs for the year July 2010 -June 2011. 
